Skip to main content


At CURE, we believe that investment in the highest quality research is the key to achieving significant progress in the fight against childhood cancer. Our focus is two-fold: we prioritize research that will reach the bedside within five years and research which will improve the outcomes for the 20% of children not surviving today’s methods of treatment. While we continue our important work to increase survival rates, it is also imperative we increase funding into safer treatments which will not compromise the rest of a child’s life. To that end, we are proud to announce $4.3 million in research grants for CURE’s fiscal year 2019–2020.

Our funding decisions are guided by our Scientific Advisory Council, a group of doctors, scientists, and researchers who conduct a thorough review of research proposals to assess both scientific merit and alignment with CURE’s goals. This year, we selected to fund 21 of the very best proposals submitted by experts at leading institutions across the country. Precision medicine continues to be a strategic focus as we enter the third year of our $4.5 million commitment which created the Aflac Cancer Center Precision Medicine Program at Children’s Healthcare of Atlanta. This unique program has already yielded significant results – giving hope to children for whom standard treatment has failed. Finally, in an effort to ensure the best and brightest minds continue to research cures for children, we will fully fund training for three pediatric oncology fellows and are providing funding to two young investigators for their research.

“We have developed an incredible partnership with CURE in the fight against childhood cancer,” said Dr. Douglas Graham, Chief of the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta. “We are so thankful for the generous gift from CURE this year to allow us to provide direct assistance to our families, fund new research projects to search for better cancer treatments, and help us train the next generation of physicians specializing in cancer care for children. The gift from CURE will also enable us to continue to develop and expand our Cancer Precision Medicine Program to enable us to provide optimal care to our most difficult to treat cancer patients. This ongoing partnership with CURE is critical to our mission to provide world class cancer care to our pediatric cancer patients.”

Our 2019-2020 Pediatric Cancer Research Initiative includes the following studies:

Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta

Douglas Graham, MD, PhD
Aflac Cancer Center Precision Medicine Program

Robert Castellino, MD
PPM1D in High-Risk, Non-SHH, Non-WNT Medulloblastoma

Zhihong Chen, PhD
Leveraging MMR Deficiency for Effective Immunotherapy in Childhood High-Grade Glioma

Deborah DeRyckere, PhD
TAM Kinases as Mediators of Chemoresistance in AML

Lubing Gu, MD
Dual Inhibition of MDM2 and XIAP for Treatment of Childhood Cancers

Lisa Ingerski, PhD
HRQOL Outcomes During Molecularly Targeted Therapy for Brain Tumors

Christopher Porter, MD
Targeting Siglec15 for the Treatment of Childhood Cancers

Erwin Van Meir, PhD
Negative Regulation of b1-Integrin Signaling by ADGRB1 in Medulloblastoma

Muxiang Zhou, MD
MYCN Inhibition as a Precision Therapy in MYCN-amplified Neuroblastoma

Augusta University Research Institute

Daquing Wu, PhD
Novel Targeted Therapy for Metastatic Osteosarcoma

Baylor College of Medicine

Alexandra Stevens, MD
A Trial of Atovaquone with Conventional Chemotherapy for Pediatric AML (ATACC AML)

Lisa L. Wang, MD
Optimizing GD2.CAR T Cell Immunotherapeutic Strategies for Relapsed Osteosarcoma and Neuroblastoma

Joanna Yi, MD
Defining the Transcriptional Control of Pediatric AML to Find New Drugs

Children’s Hospital of Philadelphia

Frank M. Balis, MD
GD2 as a Circulating Biomarker and Clinical Trial Endpoint for Neuroblastoma

Michael Chorny, PhD
Combination Therapy of Neuroblastoma Using Co-drug Impregnated Nanocarriers

Timothy Olson, MD, PhD
Bone Marrow Niche Targets to Prevent Cancer in Shwachman Diamond Syndrome

LLS PedAL Initiative, LLC

Soheil Meshinchi, MD, PhD
PedAL Initiative

Lurie Children’s Hospital of Chicago

Oren Becher, MD
Unraveling Mechanisms of Resistance to ACVR1 Inhibitors to Treat DIPG

Memorial Sloan Kettering Cancer Center

Estibaliz Lopez Rodrigo, MD
Lung Macrophage Synergy with L-MTP-PE to Target Metastatic Osteosarcoma.

Stanford University

Maria-Grazia Roncarolo, MD
Innovative Cell Therapy for Pediatric AML

Kathleen Sakamoto, MD, PhD
Niclosamide for Relapsed/Refractory Pediatric AML

Help us win the race against childhood cancer by entering Lauren’s Run.

Sunday, May 2 | Virtual